The offer

One page. Every trial.Including the ones we would tell you to avoid.

Each criterion quoted back against your own numbers, and paid for by you — so nobody can buy a place on it. That is the whole pitch, and it is also the reason it is worth anything.
No fee per enrolled patientNo sponsored trialsNo “you qualify”

Membership

$69per year

The analysis layer on every page we publish.

  • What each trial is actually testing
  • What a good result would look like
  • What the mechanism already stopped for
  • The readout calendar
  • Which trials we would tell you not to join

Research brief

$249one case

Your own facts, matched against every criterion we store.

  • Every trial your stated facts do not exclude
  • Each criterion quoted back against your numbers
  • The trials we would avoid, and why
  • No verdict, by design — no “you qualify”

Free, forever, no account:

every approved option, every recruiting trial, every published criterion, every registered site, and the sponsor's own reason a trial stopped.

What we will not do

  • Promise a place, a cure, or a result.
  • Claim to be your clinician, or to diagnose you.
  • Take a per-lead fee, even once.
  • Use urgency or fear to close a sale.
  • Read a test value or a scan into a conclusion.

What the signature tier means

The signed brief is the same document, reviewed and signed by a clinician licensed in your country. The clinician is paid by us at an hourly rate: the signature is a cost line, not the owner of the product. If we cannot name the clinician, we do not sell the signature.

This build sells the unsigned brief and the membership. The signed tier is staged behind a clinician agreement — an honest outage rather than a guess.

The first test, stated plainly

This is a measured offer, not a finished product. We are reading one number: how many people, having seen the free page and one whole sample analysis, click to buy. Under 1% means the page does not present an offer. One or two sales means continue. Four or more means it is a business.